SPOTLIGHT: Boehringer beats Bayer drug to market

Boehringer Ingelheim won European approval for its new blood thinner Pradaxa to prevent clotting in patients after orthopedic surgery. The OK lets Pradaxa beat to market its supposed future rival, Bayer's yet-to-be-approved Xarelto (rivaroxaban). Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.